This study identifies a resistance mechanism in AML leukemic stem cells to PI3K inhibition and shows that combining PI3K and EZH1/2 inhibitors overcomes resistance.

Leukemia · Sep 28, 2026Peer-reviewedCancer Biology

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

Samarpana Chakraborty, Claudia Morganti, Kimberly S. Zaldana, Bianca Rivera-Peña, H. Zhang, Divij Verma, Nadege Gitego, Feiyang Ma, Srinivas Aluri, Kith Pradhan, Shanisha Gordon-Mitchell, Ioannis Mantzaris, Mendel Goldfinger, Eric Jay Feldman, Kira Gritsman, , Aditi Shastri

This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.

Leukemia · Feb 17, 2026Peer-reviewedCancer Biology

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

Urszula Pakulska, Marta Obacz, Jerzy Woźnicki, Katarzyna Wiklik, Samarpana Chakraborty, Marta Micek, Vakul Mohanty, Diego Coelho, Elżbieta Adamczyk, Aniela Gołas, Adrianna Moszyńska, Hui Zhang, Magdalena Cybulska, Ewelina Kaniuga, Zuzanna Sandowska-Markiewicz, , Milena M. Mazan

This study shows that romaciclib combined with venetoclax overcomes venetoclax resistance in AML through synergistic apoptosis induction and suppression of resistance pathways.

bioRxiv · Jan 15, 2026 · PreprintCancer Biology